毕得医药
(688073)
| 流通市值：22.21亿 | | | 总市值：46.68亿 |
| 流通股本：4323.42万 | | | 总股本：9088.29万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 296,374,647.62 | 1,102,010,333.61 | 811,377,889.62 | 532,207,309.99 |
| 营业收入 | 296,374,647.62 | 1,102,010,333.61 | 811,377,889.62 | 532,207,309.99 |
| 二、营业总成本 | 245,523,164.31 | 931,884,986.72 | 696,947,815.87 | 456,333,477.22 |
| 营业成本 | 164,973,511.79 | 646,519,463.42 | 477,309,328.92 | 321,954,244.55 |
| 税金及附加 | 1,298,157.77 | 6,707,012.78 | 4,100,758.52 | 2,441,504.24 |
| 销售费用 | 32,356,689.97 | 126,793,835.1 | 94,315,547.68 | 60,635,280.19 |
| 管理费用 | 32,324,458.52 | 114,648,566.5 | 81,024,454.72 | 53,230,049.84 |
| 研发费用 | 15,144,994.42 | 59,054,452.56 | 45,523,716.19 | 30,050,598.68 |
| 财务费用 | -574,648.16 | -21,838,343.64 | -5,325,990.16 | -11,978,200.28 |
| 其中:利息费用 | 2,245,559.76 | 3,315,789.62 | 4,231,686.97 | 3,404,174.98 |
| 其中:利息收入 | 1,621,814.69 | 22,123,520.01 | 18,154,660.61 | 13,385,141.73 |
| 加:公允价值变动收益 | 1,749,038.24 | 3,148,107.01 | 1,269,450.8 | -323,502.63 |
| 加:投资收益 | 1,100,276.01 | 1,619,012.09 | 1,509,336.6 | 967,790.34 |
| 资产处置收益 | 240,684.9 | 856,347.2 | 833,396.64 | 610,649.76 |
| 资产减值损失(新) | -8,599,090.14 | -33,826,019.95 | -21,223,248.36 | -12,421,528.51 |
| 信用减值损失(新) | -2,479,259.23 | -3,926,949.37 | -3,619,264.95 | -2,616,286.74 |
| 其他收益 | 276,167.35 | 10,338,505.69 | 9,087,820.69 | 1,983,839.66 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 43,139,300.44 | 148,334,349.56 | 102,287,565.17 | 64,074,794.65 |
| 加:营业外收入 | 272,812.28 | 725,289.09 | 334,774.76 | 197,043.79 |
| 减:营业外支出 | 63,069.73 | 1,041,484.67 | 230,780.14 | 17,670.88 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 43,349,042.99 | 148,018,153.98 | 102,391,559.79 | 64,254,167.56 |
| 减:所得税费用 | 12,655,949.87 | 30,591,990.47 | 18,537,666.99 | 12,415,103.01 |
| 六、净利润 | 30,693,093.12 | 117,426,163.51 | 83,853,892.8 | 51,839,064.55 |
| 持续经营净利润 | 30,693,093.12 | 117,426,163.51 | 83,853,892.8 | 51,839,064.55 |
| 归属于母公司股东的净利润 | 30,693,093.12 | 117,426,163.51 | 83,853,892.8 | 51,839,064.55 |
| (一)基本每股收益 | 0.34 | 1.32 | 0.94 | 0.58 |
| (二)稀释每股收益 | 0.34 | 1.32 | 0.94 | 0.58 |
| 八、其他综合收益 | 724,099.55 | -1,641,272.74 | 3,372,706.74 | 376,362.85 |
| 归属于母公司股东的其他综合收益 | 724,099.55 | -1,641,272.74 | 3,372,706.74 | 376,362.85 |
| 九、综合收益总额 | 31,417,192.67 | 115,784,890.77 | 87,226,599.54 | 52,215,427.4 |
| 归属于母公司股东的综合收益总额 | 31,417,192.67 | 115,784,890.77 | 87,226,599.54 | 52,215,427.4 |
| 公告日期 | 2025-04-24 | 2025-04-24 | 2024-10-24 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |